417 related articles for article (PubMed ID: 29161357)
1. Nivolumab in non-small-cell lung cancer with EGFR mutation.
Yoshida H; Kim YH; Ozasa H; Nagai H; Sakamori Y; Tsuji T; Nomizo T; Yasuda Y; Funazo T; Hirai T
Ann Oncol; 2018 Mar; 29(3):777-778. PubMed ID: 29161357
[No Abstract] [Full Text] [Related]
2. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
Sato M; Watanabe S; Tanaka H; Nozaki K; Arita M; Takahashi M; Shoji S; Ichikawa K; Kondo R; Aoki N; Hayashi M; Ohshima Y; Koya T; Ohashi R; Ajioka Y; Kikuchi T
PLoS One; 2019; 14(4):e0215292. PubMed ID: 30978241
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
Lung Cancer; 2018 May; 119():14-20. PubMed ID: 29656747
[TBL] [Abstract][Full Text] [Related]
4. Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations.
Kauffmann-Guerrero D; Tufman A; Kahnert K; Bollmann BA; Reu S; Syunyaeva Z; Schneider C; Manapov F; Huber RM; Golpon H
Oncol Res Treat; 2020; 43(6):289-298. PubMed ID: 32268332
[TBL] [Abstract][Full Text] [Related]
5. Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma.
Davis A; Mahar A; Wong K; Barnet M; Kao S
Clin Lung Cancer; 2021 Sep; 22(5):e665-e667. PubMed ID: 33349572
[No Abstract] [Full Text] [Related]
6. Nivolumab improves survival for patients with advanced lung cancer.
Printz C
Cancer; 2017 Sep; 123(17):3211. PubMed ID: 28833027
[No Abstract] [Full Text] [Related]
7. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.
Guihot A; Marcelin AG; Massiani MA; Samri A; Soulié C; Autran B; Spano JP
Ann Oncol; 2018 Feb; 29(2):517-518. PubMed ID: 29206889
[No Abstract] [Full Text] [Related]
8. Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.
Prescrire Int; 2017 Apr; 26(181):93-94. PubMed ID: 30730658
[No Abstract] [Full Text] [Related]
9. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
[TBL] [Abstract][Full Text] [Related]
11. Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
Funazo T; Nomizo T; Kim YH
J Thorac Oncol; 2017 Sep; 12(9):e140-e141. PubMed ID: 28838713
[No Abstract] [Full Text] [Related]
12. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer.
Kimura H; Araya T; Yoneda T; Shirasaki H; Kurokawa K; Sakai T; Koba H; Tambo Y; Nishikawa S; Sone T; Kasahara K
Cancer Commun (Lond); 2019 Nov; 39(1):78. PubMed ID: 31753015
[No Abstract] [Full Text] [Related]
13. Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis.
Kobayashi K; Nakachi I; Naoki K; Satomi R; Nakamura M; Inoue T; Tateno H; Sakamaki F; Sayama K; Terashima T; Koh H; Abe T; Nishino M; Arai D; Yasuda H; Kawada I; Soejima K; Betsuyaku T;
Clin Lung Cancer; 2018 May; 19(3):e349-e358. PubMed ID: 29398578
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.
Kunimasa K; Nakamura H; Sakai K; Kimura M; Inoue T; Tamiya M; Nishino K; Kumagai T; Nakatsuka S; Endo H; Inoue M; Nishio K; Imamura F
Ann Oncol; 2018 Oct; 29(10):2145-2147. PubMed ID: 30099497
[No Abstract] [Full Text] [Related]
15. Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
Schouten RD; Muller M; de Gooijer CJ; Baas P; van den Heuvel M
Lung Cancer; 2018 Dec; 126():210-216. PubMed ID: 29179916
[No Abstract] [Full Text] [Related]
16. Stevens-Johnson syndrome during nivolumab treatment of NSCLC.
Salati M; Pifferi M; Baldessari C; Bertolini F; Tomasello C; Cascinu S; Barbieri F
Ann Oncol; 2018 Jan; 29(1):283-284. PubMed ID: 29045532
[No Abstract] [Full Text] [Related]
17. EGFR-TK1-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with NSCLC: When Is it Worth The Risk?
Mormile R
Pathol Oncol Res; 2019 Oct; 25(4):1665-1666. PubMed ID: 30661223
[No Abstract] [Full Text] [Related]
18. [Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC): a case report].
Tan KX; Li CY; Zhang JY; Cui HJ; Shen W; Zhang X; Sun CY; Jiang XJ; Zheng SY; Li J; Xue CX
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1047-1048. PubMed ID: 33342162
[No Abstract] [Full Text] [Related]
19. Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients.
Garassino MC; Gelibter AJ; Grossi F; Chiari R; Soto Parra H; Cascinu S; Cognetti F; Turci D; Blasi L; Bengala C; Mini E; Baldini E; Quadrini S; Ceresoli GL; Antonelli P; Vasile E; Pinto C; Fasola G; Galetta D; Macerelli M; Giannarelli D; Lo Russo G; de Marinis F
J Thorac Oncol; 2018 Aug; 13(8):1146-1155. PubMed ID: 29730379
[TBL] [Abstract][Full Text] [Related]
20. Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung.
Roesel C; Kambartel K; Kopeika U; Berzins A; Voshaar T; Krbek T
Curr Oncol; 2019 Apr; 26(2):e270-e273. PubMed ID: 31043837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
